Larimar Therapeutics Inc

LRMR

Company Profile

  • Business description

    Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

  • Contact

    Three Bala Plaza East
    Suite 506
    Bala CynwydPA19004
    USA

    T: +1 844 511-9056

    https://www.larimartx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    65

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,963.5029.200.33%
CAC 407,800.8833.70-0.43%
DAX 4023,970.36247.14-1.02%
Dow JONES (US)44,837.5664.36-0.14%
FTSE 1009,081.4438.87-0.43%
HKSE25,562.13173.780.68%
NASDAQ21,178.5870.270.33%
Nikkei 22540,998.27457.96-1.10%
NZX 50 Index12,928.0117.270.13%
S&P 5006,389.771.130.02%
S&P/ASX 2008,697.7030.800.36%
SSE Composite Index3,597.944.280.12%

Market Movers